Compare Definium Therapeutics Inc. Common Shares (DFTX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs GeneDx Holdings Corp — how do they compare? Definium Therapeutics Inc. Common Shares trades at $37.54 (market cap $4.59B), while GeneDx Holdings Corp trades at $68.31 (market cap $2.02B). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 2.3× GeneDx Holdings Corp's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and GeneDx Holdings Corp for 19 Days on average.
| DFTX | WGS | |
|---|---|---|
Market Cap | $4.59B | $2.02B |
Volume | 2,103,937 | 734,640 |
Sector | Health | Health |
52-Week High | $48.45 | $167.51 |
52-Week Low | $10.68 | $34.51 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $3.55B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
